Maynard Um
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS)
-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Tops Q2 EPS by 2c, provides guidance
-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Files $250M Mixed Shelf
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS)
-
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

